Compare · CUPR vs NVO
CUPR vs NVO
Side-by-side comparison of Cuprina Holdings (Cayman) Limited (CUPR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CUPR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 31544.3x CUPR ($6.1M).
- Over the past year, CUPR is down 95.2% and NVO is down 44.9% - NVO leads by 50.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for CUPR).
- NVO has more recent analyst coverage (25 ratings vs 0 for CUPR).
- Company
- Cuprina Holdings (Cayman) Limited
- Novo Nordisk A/S
- Price
- $2.36-0.42%
- $43.34+1.30%
- Market cap
- $6.1M
- $191.15B
- 1M return
- +18.06%
- -7.74%
- 1Y return
- -95.25%
- -44.93%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CUPR
- Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
- Cuprina Holdings announces 1-for-8 Share Consolidation
- SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited
- Amendment: SEC Form 6-K/A filed by Cuprina Holdings (Cayman) Limited
- SEC Form 20-F filed by Cuprina Holdings (Cayman) Limited
- SEC Form 3 filed by new insider Lee Jimmy Peng Siew
- SEC Form 3 filed by new insider Raina Natasha Kaur
- SEC Form 3 filed by new insider Teo Peng Kwang
- SEC Form 3 filed by new insider Koh Pee Keat
- SEC Form 3 filed by new insider Quek David Yong Qi
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care